ArticleScientific reports2024
Antifungal susceptibility and virulence determinants profile of candida species isolated from patients with candidemia.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation.Applied microbiology and biotechnology · 2026Article
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- Exploratory analysis of biofilm formation and virulence gene expression in Acinetobacter baumannii-Candida albicans co-cultured isolates from urinary tract infections.Scientific reports · 2026Article
- Vulvovaginal candidiasis among Yemeni women: prevalence of Candida species, biofilm formation rates, antifungal susceptibility patterns, and biofilm-associated genes ALS1 and HWP1.BMC microbiology · 2026Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- Acute high shear stress enhances fungal cell/substrate adhesion.Microbiology spectrum · 2026Article
- Candida species identified by MAL-DI-TOF and antifungal susceptibility in hospitalized patients with COVID-19 in Peru.Revista peruana de medicina experimental y salud publica · 2026Observational
- HTD1265 Disrupts GimC-Dependent Cellular Processes inPathogens (Basel, Switzerland) · 2026Article
- Coriander leaf essential oil as an immunomodulator: Enhancing NF-κB-driven RAW246.7 murine macrophages response to Candida albicans.PloS one · 2026Article
- In Vitro Evaluation of 5-Fluorouridine as an Adjuvant to Antifungal Drugs and Molecular Insights into Resistance to This Compound inInternational journal of molecular sciences · 2025Article
- Structural and Functional Insights into Viral and Fungal Proteins Involved in Chronic Inflammation and Their Biologic Treatments.Pharmaceutics · 2025Review
- Fluconazole-resistant vulvovaginal candidiasis in reproductive-age women: a study from Himalayan country.BMC microbiology · 2025Article
- 1,5-Diarylidene-4-Piperidones as Promising Antifungal Candidates AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Disruption of the ATP-dependent unfoldase ClpX reverses antifungal resistance in Cryptococcus neoformans.Nature communications · 2025Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
- Detection and taxonomic identification of emerging pathogenic yeasts in surface waters from Lagoon Systems in Rio de Janeiro, Brazil.Environmental monitoring and assessment · 2025Article
- Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance.Microorganisms · 2025Review
- Epidemiology risk factors and antifungal resistance patterns ofFrontiers in microbiology · 2025Article
- Research progress on the drug resistance mechanisms ofFrontiers in microbiology · 2025Review
- Antimicrobial Effect of Common Bacterial Pigments on Clinically Significant Microorganisms.Scientifica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida is the most prevalent fungal bloodstream infection (BSI) with a high mortality rate among hospitalized patients. Another concern facing physicians is rising global incidence of drug-resistant Candida. This study aimed to characterize the prevalence, antifungal susceptibility, biofilm formation, and virulence genes (HWP1, ALS1, SAP2) of different Candida spp. isolated from patients with candidemia. 52 isolates of Candida spp. were identified from blood cultures by chromogenic Candida agar and confirmed by the VITEK 2 system. Isolates were tested for antifungal susceptibility by disk diffusion and VITEK 2 system. Biofilm formation and investigated genes were detected by the Congo red method and conventional PCR, respectively. Candida spp. caused 2.3% of detected BSIs, of which 32.7% were caused by Candida albicans (C. albicans) and 67.3% by non-albicans Candida (NAC), with the predominance of C. tropicalis (25%), followed by C. parapsilosis (17.3%), and C. krusei (13.5%). The susceptibility rates to fluconazole, voriconazole, caspofungin, micafungin, amphotericin B, and flucytosine were 64.7%, 76.5%, 100.0%, 100%, 100.0%, and 100.0% in C. albicans, while 53.6%, 71.4%, 91.4%, 91.4%, 94.3%, and 94.3% in NAC, respectively. Biofilm production, HWP1, ALS1, and SAP2 were detected in 70.6%, 82.4%, 76.5%, and 52.9% of C. albicans and 74.3%, 85.7%, 80.0%, and 48.6% of NAC, respectively. There is remarkable shift to NAC BSIs and high azole resistance. Antifungal stewardship and analysis of risk factors associated with this shift are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.